VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 158 filers reported holding VERVE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $51,000 | -78.3% | 10,490 | -40.6% | 0.00% | – |
| Q1 2024 | $235,000 | +25.7% | 17,651 | +31.2% | 0.00% | – |
| Q4 2023 | $187,000 | -28.9% | 13,451 | -32.3% | 0.00% | – |
| Q3 2023 | $263,000 | -17.8% | 19,880 | +16.4% | 0.00% | – |
| Q2 2023 | $320,000 | +98.8% | 17,079 | +52.2% | 0.00% | – |
| Q1 2023 | $161,000 | -33.7% | 11,223 | -10.4% | 0.00% | – |
| Q4 2022 | $243,000 | -2.8% | 12,523 | +71.9% | 0.00% | – |
| Q3 2022 | $250,000 | +1370.6% | 7,286 | +544.2% | 0.00% | – |
| Q2 2022 | $17,000 | -70.7% | 1,131 | -56.0% | 0.00% | – |
| Q1 2022 | $58,000 | -77.7% | 2,571 | -63.4% | 0.00% | – |
| Q4 2021 | $260,000 | -37.5% | 7,026 | -20.7% | 0.00% | – |
| Q3 2021 | $416,000 | -2.8% | 8,860 | +24.8% | 0.00% | – |
| Q2 2021 | $428,000 | – | 7,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |